Lipella Pharmaceuticals
LIPO
LIPO was delisted on the 18th of June, 2025.
4 hedge funds and large institutions have $82.5K invested in Lipella Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.
0.03% less ownership
Funds ownership: 0.12% → 0.08% (-0.03%)
20% less capital invested
Capital invested by funds: $104K → $82.5K (-$21.1K)
33% less funds holding
Funds holding: 6 → 4 (-2)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$3.14K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$25.6K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.98K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.19K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$100 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $73.9K | -$4.98K | -319 | -7% |
|
|
2
UBS Group
Zurich,
Switzerland
| $5.18K | +$3.14K | +201 | +197% |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $3.44K | -$1.19K | -76 | -27% |
|
4
Wells Fargo
San Francisco,
California
| $19 | – | – | – |
|
|
TSS
5
Two Sigma Securities
New York
| – | -$25.6K | -1,642 | Closed |
|
|
6
Fidelity Investments
Boston,
Massachusetts
| – | -$100 | -7 | Closed |
|
LIPO Hedge Fund Activity: Q2 2023 in Review
4 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Lipella Pharmaceuticals (LIPO) for Q2 2023, worth a combined $82.5K — down 20% from $104K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of LIPO and 0 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 1 added.
The largest buyer was UBS Group, adding an estimated $3.14K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $25.6K sold.
- 4 institutional investors held Lipella Pharmaceuticals (LIPO) as of Q2 2023, down from 6 in Q1 2023.
- Funds reported $82.5K of Lipella Pharmaceuticals stock for Q2 2023, down 20% quarter-over-quarter.
- 0 funds opened new Lipella Pharmaceuticals positions in Q2 2023 and 2 closed out, a net change of -2 holders.
- The largest Lipella Pharmaceuticals buyer in Q2 2023 was UBS Group, an estimated $3.14K added.
- The largest Lipella Pharmaceuticals seller in Q2 2023 was Two Sigma Securities, an estimated $25.6K sold.
Based on aggregated 13F filings for Q2 2023.